S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Is This The End of Capitalism? (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
The Next Big Crisis Is Here (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Is This The End of Capitalism? (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
The Next Big Crisis Is Here (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Is This The End of Capitalism? (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
The Next Big Crisis Is Here (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Is This The End of Capitalism? (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
The Next Big Crisis Is Here (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
NASDAQ:ITCI

Intra-Cellular Therapies - ITCI Stock Forecast, Price & News

$48.77
+0.53 (+1.10%)
(As of 01/26/2023 12:00 AM ET)
Add
Compare
Today's Range
$48.09
$49.12
50-Day Range
$47.72
$54.45
52-Week Range
$42.42
$66.00
Volume
309,742 shs
Average Volume
542,738 shs
Market Capitalization
$4.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$69.29

Intra-Cellular Therapies MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
42.1% Upside
$69.29 Price Target
Short Interest
Healthy
2.73% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
0.70mentions of Intra-Cellular Therapies in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$4.76 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.87) to ($1.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

390th out of 1,048 stocks

Pharmaceutical Preparations Industry

191st out of 513 stocks


ITCI stock logo

About Intra-Cellular Therapies (NASDAQ:ITCI) Stock

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm's lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.

Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
ITCI.PH - | Stock Price & Latest News | Reuters
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Intra-Cellular Therapies Has My Attention
Is Intra-Cellular Therapies (ITCI) Stock a Worthy Buy?
ITCI Intra-Cellular Therapies, Inc.
See More Headlines
Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Company Calendar

Last Earnings
11/03/2022
Today
1/27/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ITCI
Employees
512
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$69.29
High Stock Price Forecast
$93.00
Low Stock Price Forecast
$49.00
Forecasted Upside/Downside
+42.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-284,130,000.00
Net Margins
-158.39%
Pretax Margin
-158.39%

Debt

Sales & Book Value

Annual Sales
$83.80 million
Book Value
$5.13 per share

Miscellaneous

Free Float
91,201,000
Market Cap
$4.62 billion
Optionable
Optionable
Beta
1.18

Key Executives

  • Sharon MatesSharon Mates
    Chairman, President & Chief Executive Officer
  • Lawrence J. Hineline
    Chief Financial Officer, Treasurer & SVP-Finance
  • Robert E. Davis
    Chief Scientific Officer & Senior Vice President
  • Suresh DurgamSuresh Durgam
    Chief Medical Officer & Senior Vice President
  • Karen Patruno Sheehy
    Chief Compliance Officer & Senior Vice President













ITCI Stock - Frequently Asked Questions

Should I buy or sell Intra-Cellular Therapies stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ITCI shares.
View ITCI analyst ratings
or view top-rated stocks.

What is Intra-Cellular Therapies' stock price forecast for 2023?

6 Wall Street analysts have issued 12-month price targets for Intra-Cellular Therapies' shares. Their ITCI share price forecasts range from $49.00 to $93.00. On average, they anticipate the company's share price to reach $69.29 in the next twelve months. This suggests a possible upside of 42.1% from the stock's current price.
View analysts price targets for ITCI
or view top-rated stocks among Wall Street analysts.

How have ITCI shares performed in 2023?

Intra-Cellular Therapies' stock was trading at $52.92 at the beginning of 2023. Since then, ITCI stock has decreased by 7.8% and is now trading at $48.77.
View the best growth stocks for 2023 here
.

Are investors shorting Intra-Cellular Therapies?

Intra-Cellular Therapies saw a decline in short interest in January. As of January 15th, there was short interest totaling 2,590,000 shares, a decline of 19.3% from the December 31st total of 3,210,000 shares. Based on an average daily volume of 627,400 shares, the short-interest ratio is currently 4.1 days.
View Intra-Cellular Therapies' Short Interest
.

When is Intra-Cellular Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our ITCI earnings forecast
.

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) announced its quarterly earnings data on Thursday, November, 3rd. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.29. The biopharmaceutical company had revenue of $71.87 million for the quarter, compared to analysts' expectations of $64.95 million. Intra-Cellular Therapies had a negative net margin of 158.39% and a negative trailing twelve-month return on equity of 45.52%.

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (0.21%), Assenagon Asset Management S.A. (0.08%), Strs Ohio (0.02%), Quantum Private Wealth LLC (0.02%), Hennion & Walsh Asset Management Inc. (0.01%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates and Suresh K Durgam.
View institutional ownership trends
.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $48.77.

How much money does Intra-Cellular Therapies make?

Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $4.62 billion and generates $83.80 million in revenue each year. The biopharmaceutical company earns $-284,130,000.00 in net income (profit) each year or ($3.32) on an earnings per share basis.

How many employees does Intra-Cellular Therapies have?

The company employs 512 workers across the globe.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for the company is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at ir@intracellulartherapies.com, or via fax at 646-440-9334.

This page (NASDAQ:ITCI) was last updated on 1/27/2023 by MarketBeat.com Staff